Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Neuropeptide Y (NPY)-containing neurons are depleted in the cortices of individuals with Alzheimer disease (AD), yet spared in the striatum of patients with Huntington chorea. It is unknown whether this neuronal phenotype is inherently susceptible to the neurodegenerative processes that are a hallmark of AD. To study this question, the murine trisomy 16 model of Down syndrome and Alzheimer disease was investigated. Since trisomic fetuses die in utero, studies were carried out on primary cultures of dissociated cortical neurons. These were prepared from 15-d gestational trisomy 16 fetuses and their littermate euploid controls, and examined by immunocytochemical staining for neuropeptide Y at 7 and 12 d in vitro. Trisomy 16 neurons were also grown on euploid glial carpets, whereas euploid neurons were grown on trisomic glia. The results demonstrate a significant increase in the number of NPY neurons and a stunting in the dendritic arbor of these neurons in trisomic vs euploid cortex. Both of these parameters could be normalized by direct contact with euploid glia. When euploid cortex was plated on trisomic glia, the number of NPY neurons and their morphology were altered so that they began to resemble trisomic NPY cortical neurons. These results indicate a dysregulation of NPY neuronal expression and differentiation in trisomy 16 cortex that are modifiable by interaction with euploid glia and imply an abnormal trophic (glial) environment in trisomic cortex.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Caserta, M. T. (1994). Neuropeptide Y immunoreactive neurons in murine trisomy 16 cortical cultures. Plasticity of expression and differentiation. Molecular and chemical neuropathology. https://doi.org/10.1007/bf03160106

Vancouver

Caserta MT. Neuropeptide Y immunoreactive neurons in murine trisomy 16 cortical cultures. Plasticity of expression and differentiation. Molecular and chemical neuropathology. 1994. doi:10.1007/bf03160106. PMID: 7993528.

BibTeX

@article{caserta1994-7993528,
  author  = {Caserta, M. T.},
  title   = {{Neuropeptide Y immunoreactive neurons in murine trisomy 16 cortical cultures. Plasticity of expression and differentiation}},
  journal = {Molecular and chemical neuropathology},
  year    = {1994},
  doi     = {10.1007/bf03160106},
  pmid    = {7993528},
  url     = {https://doi.org/10.1007/bf03160106}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In cultured cortical neurons from a mouse model of Down syndrome, the number and shape of neuropeptide Y neurons were abnormal and could be normalized by contact with normal glial cells. This is a cell-culture study and provides no treatment, cure or prevention for Alzheimer's disease.

Study details

How this study scored 30/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 2 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 30 of 100.30 of 100 points earned70 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Molecular and chemical neuropathology)
Journal's citation record 0 / 4 Molecular and Chemical Neuropathology: journal h-index 56 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1994 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “murine”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 11 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 34 year(s) since 1994
Impact for its field and year 1 / 6 Cited 1.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 3 other studies in this library
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Maria T. Caserta: h-index 9 (OpenAlex, whole career)
Institution's track record 2 / 3 Northwestern University: institution h-index 1,592 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 7993528)
Free to read 0 / 2 Behind a paywall — scores zero
Total 30 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

3 studies in the alzhub library list this one in their references.

Related studies in Down syndrome and Alzheimer's

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →